SCHEDULE: Armistice Capital Cuts Shuttle Pharma Stake Below 5%

Armistice Capital and Steven Boyd have reduced their beneficial ownership in Shuttle Pharmaceuticals Holdings, Inc. to 4.99% of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock.
• This represents 4.99% of the company's common stock, based on information from the issuer.
• The reporting persons hold shared voting and shared dispositive power over all 56,237 shares.
• The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, LLC.
• Armistice Capital, LLC, as the investment manager, exercises voting and investment power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own these securities.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by Armistice Capital and Steven Boyd to just under 5%, which typically signals a decreased stake by a significant institutional investor. While not an active divestment, dropping below the 5% threshold can be perceived as a negative signal by the market, suggesting a potential loss of conviction or a strategic portfolio adjustment.

Positives

• The filing confirms that the investment is passive and not intended to influence or change control of the issuer.

Negatives

• The beneficial ownership percentage has dropped to 4.99%, falling below the 5% threshold, which often signals a reduction in a significant institutional investor's stake.

Future Outlook

NA

Industry Context

This is a standard ownership disclosure for a publicly traded company. A reduction in beneficial ownership by an institutional investor like Armistice Capital to below the 5% threshold can be interpreted by the market as a strategic portfolio adjustment or a re-evaluation of the investment, though this filing does not provide specific reasons. For a pharmaceutical company, changes in institutional ownership are often closely monitored as they can reflect broader market sentiment or specific views on the company's pipeline or strategic direction.

Comparison to Industry Standards

• Institutional investors, including hedge funds and asset managers like Armistice Capital, frequently adjust their positions in small-cap biotechnology or pharmaceutical companies such as Shuttle Pharmaceuticals Holdings, Inc.
• A reduction in a stake to below the 5% threshold, while not necessarily a direct 'sell' signal, indicates that the investor no longer holds a significant enough position to require ongoing public disclosure of their holdings unless they cross the threshold again.
• Comparable situations involve other investment funds adjusting their passive stakes in companies within the biotech sector based on their internal investment mandates, risk assessments, or portfolio rebalancing strategies.

Stakeholder Impact

• Shareholders may interpret the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and the company's share price.

Key Dates

Recommendation

The filing indicates that Armistice Capital and Steven Boyd have reduced their beneficial ownership in Shuttle Pharmaceuticals Holdings, Inc. to 4.99%, falling below the 5% disclosure threshold. While this is a passive filing and not an active divestment, a reduction in a significant institutional stake can be viewed negatively by the market, potentially signaling a re-evaluation of the investment or portfolio rebalancing. However, without further context on the specific reasons for the reduction, a 'hold' recommendation is appropriate, advising investors to monitor future developments and the company's performance.

Keywords

Shuttle Pharmaceuticals Holdings, Armistice Capital, Steven Boyd, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional ownership, investment management